



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### NexGard 28 mg Chewable Tablets for Dogs >4-10 kg Vm 04491/5029

• 24 April 2023	Change in the name or address or contact details of a qualified person for pharmacovigilance.
• 17 April 2023	Change in the Summary of Product Characteristics, Labelling or Package Leaflet due to new clinical data. Addition of a new therapeutic indication or modification of an approved one. Addition of a new therapeutic indication or modification of an approved one.
• 14 October 2022	Addition of a site of batch control.
• 14 October 2022	Addition of a site responsible for primary packaging.
• 13 October 2022	Addition of a manufacturing site for the manufacturing process of the finished product.
• 23 August 2022	Change in address of manufacturer of the finished product.
• 08 June 2022	Changes to labelling.
• 29 April 2022	Change in immediate packaging of the active substance.
• 28 April 2022	Increase in batch size (from 636 kg to 636 kg or 656 kg) of the active substance used in the manufacturing process of the active substance.
• 15 February 2022	Deletion of a supplier of packaging components or devices.
• 02 September 2021	Change in shape or dimensions of the container or closure (immediate packaging). Minor change in the manufacturing process of the finished product. Deletion of a non-significant specification parameter of an excipient.
• 25 March 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.